Welcome to our dedicated page for AstraZeneca SEC filings (Ticker: AZNCF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AZNCF SEC filings page on Stock Titan provides access to AstraZeneca PLC regulatory disclosures as furnished to the U.S. Securities and Exchange Commission. AstraZeneca uses Form 6-K reports to share information on clinical trial results, regulatory milestones and portfolio updates for its prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Recent 6-K filings show the depth of information available to investors and researchers. One report details the KOMET Phase III trial of Koselugo (selumetinib) in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas, supporting a positive opinion from the European Medicines Agency’s CHMP. Another filing summarises the WAYPOINT Phase III trial of Tezspire (tezepelumab) in chronic rhinosinusitis with nasal polyps, including co-primary endpoints on nasal polyp score and nasal congestion.
Additional 6-Ks provide high-level data from the TULIP-SC Phase III trial of Saphnelo (anifrolumab) in systemic lupus erythematosus and an update on the RESOLUTE Phase III trial of Fasenra (benralizumab) in chronic obstructive pulmonary disease. These documents also restate AstraZeneca’s standard company description, outlining its global footprint, therapeutic focus and Respiratory & Immunology franchise.
On Stock Titan, users can review these filings as they are made available from EDGAR and use AI-powered summaries to understand the key points of each document, such as trial design, primary and secondary endpoints, safety profiles and regulatory implications, without reading every technical detail.
AstraZeneca PLC reports the issuance by its subsidiary AstraZeneca Finance LLC of three new U.S. dollar fixed rate note tranches, fully and unconditionally guaranteed by AstraZeneca PLC. These consist of $650,000,000 4.000% notes due 2031, $600,000,000 4.300% notes due 2033, and $750,000,000 4.600% notes due 2036.
The company is furnishing this information so the related underwriting, pricing, officer certificates, and legal opinions can be incorporated into its existing shelf registration statement on Form F-3.
AstraZeneca PLC reports its current voting share capital. As at 28 February 2026, the company has 1,550,966,708 issued ordinary shares of US$0.25 each with voting rights, and no shares held in treasury. This means the total number of voting rights is 1,550,966,708.
Shareholders can use this total voting rights figure as the denominator when calculating whether they must notify the UK Financial Conduct Authority of holdings or changes in their interest under the Disclosure and Transparency Rules.
AstraZeneca PLC has priced a
The tranches comprise
AstraZeneca expects to use the net proceeds for general corporate purposes, which may include refinancing existing debt. The company states that this bond issuance does not impact its financial guidance for
AstraZeneca PLC has filed its 2025 Annual Report on Form 20-F with the US Securities and Exchange Commission. The report can be viewed on both the SEC website and the company’s own site, giving investors access to detailed audited financial and business information.
The company will provide any security holder with a hard copy of its complete audited financial statements free of charge upon request through its Company Secretary in Cambridge, UK.
AstraZeneca PLC has filed its Form 20‑F annual report for the year ended 31 December 2025, summarising its global operations, risks and product portfolio. The company lists ordinary shares and multiple long-dated notes on the New York Stock Exchange and reports 1,550,907,927 ordinary shares outstanding at year-end.
The filing incorporates by reference the detailed 2025 Annual Report, while this document highlights extensive risk factors across product development, pricing, supply chain, cybersecurity, AI, legal and sustainability areas. It presents a broad late‑stage pipeline in oncology, cardiovascular, respiratory and rare disease, with numerous Phase III trials and anticipated data readouts beyond 2026.
AstraZeneca also discloses patent expiry ranges for key marketed medicines such as Tagrisso, Imfinzi, Farxiga, Calquence, Ultomiris and others, flagging ongoing generic challenges and potential ‘at risk’ launches. Selected product sales data show Tagrisso at $7,254 million and Farxiga/Forxiga at $6,670 million in 2025, underlining oncology and CVRM as major revenue drivers.
AstraZeneca PLC has published its 2025 Annual Report and Form 20-F information. The report is available on the company’s website and will also be submitted to the UK National Storage Mechanism for public inspection. Printed copies will be sent to shareholders in due course.
The company confirmed that its Annual General Meeting will take place on 9 April 2026. The Annual Report includes key regulated information such as principal risks and uncertainties, the directors’ responsibility statement for the financial statements and directors’ report, and a statement on related party transactions.
AstraZeneca PLC reported upcoming changes to its Board of Directors. Non-Executive Director Nazneen Rahman will retire from the Board at the conclusion of the Company’s AGM on 9 April 2026, after serving since 2017 in several key committee roles.
At the same AGM, Tony Mok will become Chair of the Sustainability Committee and join the Nomination and Governance Committee, while Birgit Conix will join the Sustainability Committee. The company highlights Rahman’s contributions to science, sustainability and governance during her tenure.
AstraZeneca reports that the US Food and Drug Administration approved Calquence (acalabrutinib) plus venetoclax as the first all-oral, fixed-duration combination for adults with chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma in the 1st-line setting.
The 14‑month regimen is supported by the Phase III AMPLIFY trial, where 77% of patients on Calquence plus venetoclax were progression free at three years versus 67% on standard chemoimmunotherapy, and the combo reduced the risk of disease progression or death by 35% (hazard ratio 0.65).
Median progression-free survival was not reached for the Calquence combination versus 47.6 months for chemoimmunotherapy, and safety was consistent with the known Calquence profile without new safety signals.
AstraZeneca PLC reported strong full-year 2025 results with broad-based growth. Total Revenue rose to $58,739m, up 8% at constant exchange rates, led by Oncology, BioPharmaceuticals and Rare Disease. Reported EPS increased to $6.60, up 43% at constant exchange rates, while Core EPS grew 11% to $9.16.
The company highlighted 16 positive Phase 3 readouts and 43 major approvals over the last 12 months and now counts 16 blockbuster medicines. A total dividend of $3.20 per share for 2025 was declared, up 3%, with an intended increase to $3.30 per share in 2026.
For 2026, AstraZeneca guides to mid‑to‑high single‑digit Total Revenue growth and low double‑digit Core EPS growth at constant exchange rates, with a Core tax rate of 18–22%. The company also began trading ordinary shares on the NYSE, announced $15bn of planned investment in China through 2030, and signed major pipeline and collaboration deals, including a $1.2bn upfront weight‑management portfolio agreement with CSPC and sizeable oncology transactions with Jacobio Pharma and AbelZeta.